Compare AVX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | PMVP |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Canada | United States |
| Employees | 3 | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 73.1M |
| IPO Year | N/A | 2020 |
| Metric | AVX | PMVP |
|---|---|---|
| Price | $0.60 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 337.2K | ★ 441.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.83 |
| 52 Week High | $2.27 | $1.88 |
| Indicator | AVX | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 60.10 |
| Support Level | $0.55 | $1.37 |
| Resistance Level | $0.84 | $1.53 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 47.79 | 100.00 |
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.